EB66® cell-based pandemic
influenza vaccine manufacturing

In March 2014, Valneva announced the first ever marketing approval for a human vaccine produced in the EB66® cell line.

The approval was granted by the Japanese health authorities to the Chemo-Sero Therapeutic Research Institute (Kaketsuken), a co-development partner of GlaxoSmithKline (GSK), for a pandemic H5N1 influenza vaccine.

The vaccine has been developed in accordance with the Japanese government’s plan to rapidly respond to an influenza pandemic both before and during an outbreak.

Kaketsuken has recently completed the construction of a state-of-the-art manufacturing facility in Kumamoto (Japan) with a pandemic production capacity of approximately 80 million doses.

In parallel, Kaketsuken is actively pursuing the development of its EB66® based seasonal influenza vaccines in EB66® cells.

Kaketsuken is a co-development partner with GlaxoSmithKline Vaccines to develop and market pandemic and seasonal influenza vaccines in Japan.

Please update your browser...